FOLLOWUS
Danshen injection as adjuvant treatment for unstable angina pectoris: A systematic review and meta-analysis
Danshen injection as adjuvant treatment for unstable angina pectoris: A systematic review and meta-analysis
- 中国结合医学杂志（英文版） 2017年23卷第4期 页码：306-311
- Affiliations：
Department of Clinical Pharmacology of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 81473547) and Scientic Research Innovation Team Project of Beijing University of Chinese Medicine, China (No. 2011-CXTD-14)
DOI：10.1007/s11655-016-2272-0
中图分类号：纸质出版日期：2017，
网络出版日期：2016-12-5，
Scan for full text
Wu, Jr., Liu, S., Zhang, Xm. et al. Danshen injection as adjuvant treatment for unstable angina pectoris: A systematic review and meta-analysis., Chin. J. Integr. Med. 23, 306–311 (2017). https://doi.org/10.1007/s11655-016-2272-0
Jia-rui Wu, Shi Liu, Xiao-meng Zhang, et al. Danshen injection as adjuvant treatment for unstable angina pectoris: A systematic review and meta-analysis[J]. Chinese Journal of Integrative Medicine, 2017,23(4):306-311.
Wu, Jr., Liu, S., Zhang, Xm. et al. Danshen injection as adjuvant treatment for unstable angina pectoris: A systematic review and meta-analysis., Chin. J. Integr. Med. 23, 306–311 (2017). https://doi.org/10.1007/s11655-016-2272-0 DOI：
Jia-rui Wu, Shi Liu, Xiao-meng Zhang, et al. Danshen injection as adjuvant treatment for unstable angina pectoris: A systematic review and meta-analysis[J]. Chinese Journal of Integrative Medicine, 2017,23(4):306-311. DOI： 10.1007/s11655-016-2272-0.
摘要
To systematically evaluate the clinical effectiveness and safety of Danshen Injection (丹参注射液
DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using literature databases
a thorough and systematic retrieval of randomized controlled trials (RCTs) comparing DS plus WM with WM was conducted from inception to April 2015. The extracted data from included studies was analyzed by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies
and Begg’s and Egger’s tests conducted by Stata 12.0 were used to evaluate the potential presence of publication bias. A total of 17 RCTs
which involving 1
433 participants
were identified and reviewed. The meta-analysis indicated that the combined use of DS and WM was significantly superior to WM alone for UAP in terms of the total effectiveness rate of angina pectoris [risk ratio (RR) =1.23
95% confidence interval (CI): 1.17
1.29
P<0.01] and the total effectiveness rate of electrocardiogram (ECG) [RR=1.18
95%CI: 1.06
1.30
P=0.001]. Additionally
DS could also further reduce the content of fibrinogen
adjust blood lipid level
correct T wave inversion
and so on. Fifteen adverse drug reactions were reported in two studies
Four of which appeared in the experimental group. Based on the systematic review
the combined use of DS and WM was more effective than WM alone
it can be further widely used in clinic
however
there was no exact conclusion for its safety.
Abstract
To systematically evaluate the clinical effectiveness and safety of Danshen Injection (丹参注射液
DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using literature databases
a thorough and systematic retrieval of randomized controlled trials (RCTs) comparing DS plus WM with WM was conducted from inception to April 2015. The extracted data from included studies was analyzed by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies
and Begg’s and Egger’s tests conducted by Stata 12.0 were used to evaluate the potential presence of publication bias. A total of 17 RCTs
which involving 1
433 participants
were identified and reviewed. The meta-analysis indicated that the combined use of DS and WM was significantly superior to WM alone for UAP in terms of the total effectiveness rate of angina pectoris [risk ratio (RR) =1.23
95% confidence interval (CI): 1.17
1.29
P<0.01] and the total effectiveness rate of electrocardiogram (ECG) [RR=1.18
95%CI: 1.06
1.30
P=0.001]. Additionally
DS could also further reduce the content of fibrinogen
adjust blood lipid level
correct T wave inversion
and so on. Fifteen adverse drug reactions were reported in two studies
Four of which appeared in the experimental group. Based on the systematic review
the combined use of DS and WM was more effective than WM alone
it can be further widely used in clinic
however
there was no exact conclusion for its safety.
关键词
Danshen Injectionunstable angina pectorissystemic reviewmeta-analysis
Keywords
Danshen Injectionunstable angina pectorissystemic reviewmeta-analysis
references
Han YJ, Sheng XG. Treatment situation of unstable angina pectoris. J Tradit Chin Med (Chin) 2007;48:945.
Parikh R, Kadowitz PJ. Angina pectoris: current therapy and future treatment options. Expert Rev Cardiovascular Therapy 2014;12:175–186.
Liu DH. 395 cases of coronary heart disease angina pectoris syndrome characteristics of traditional Chinese medicine research. J Tradit Chin Med (Chin) 2002;36:617.
Zhang ZH, Zhao HX. Clinical research in the treatment with Danshen Injection for unstable angina pectoris. J Emerg Tradit Chin Med (Chin) 2001;10(5):267.
International Heart Association and WHO Standardization Joint Workshops. Nomenclature and diagnostic criteria of ischemic heart disease. Chin J Cardio (Chin) 1981;9(1):75.
Editorial Committee of Chinese Journal of Cardiology. Diagnosis of unstable angina pectoris. Chin J Cardio (Chin) 2000;28:409.
The Editorial Board of Chinese Journal of Cardiology in Cardiovascular Medicine Groups. Guiding principles of clinical research of cardiovascular system drug. Chin J Clin Pharm (Chin) 1988;4:245–255.
Higgins JP, Altman DG, Gφtzsche PC, Jlini P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in random trials. BMJ 2011;343:d5928.
Review Manager (RevMan, Computer program). Version5.2. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration; 2012.
Zheng MH, ed. Applications and example analyzation of the meta-analysis software. Beijing: People’s Medical Publishing House; 2013:4.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101.
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
Cao C. Clinical study in 104 cases of Danshen Injection in treatment of unstable angina pectoris. Chin Med Guid (Chin) 2010;12:249–251.
Cheng RQ. Clinical study in 45 cases of Danshen Injection in treatment of unstable angina pectoris. Chin Med Guid (Chin) 2007;4(23):77–78.
Ding QY, Zou WW. The clinical effectiveness of Danshen Injection combined with simvastatin in treating unstable angina pectoris. Med Inform (Chin) 2010;6:1537.
Hu YZ, Yang B, Liu DB, Feng DH. The effects of Danshen Injection on intercellular adhesion molecules-1 in treatment of acute cerebral infarction. Chin Med Guid (Chin) 2004;23:807–809.
Li X. The clinical effectiveness of Danshen Injection combined with Western medicine in treating unstable angina pectoris. J Hunan Univ Chin Med (Chin) 2006;26(2):28–29.
Liang HS, Li KF, Deng WX. Clinical research in the treatment with Danshen injection for unstable angina pectoris. Chin J Pract Inter Med (Chin) 2006;26:198–199.
Pan LP. Clinical research in the treatment with Danshen Injection for unstable angina pectoris. China Foreign Med Treat (Chin) 2011;16:74.
Qian YL, Sun YP, Chen B. Clinical study in 32 cases of Danshen Injection in treating patients with unstable angina pectoris. Chin J Integr Tradit West Med (Chin) 2000;20:700–701.
Shao M. The clinical effectiveness of Danshen Injection in treating unstable angina pectoris. J Anhui Univ Tradit Chin Med (Chin) 2003;22:13–16.
Song SL, Zheng JY, Xin CY. The clinical effectiveness of Danshen Injection in treating unstable angina pectoris. China Health Care Nutrition (Chin) 2013;12:420–421.
Wang XL, Zhang YL. The clinical effectiveness of Danshen Injection combined with isosorbide mononitrate in treating unstable angina pectoris. Chin J Primary Med Pharm (Chin) 2007;14:1388.
Wang XB, Wu HY. The clinical effectiveness of Danshen Injection combined with Western medicine in treating unstable angina pectoris. J Pract Tradit Chin Inter Med (Chin) 2013;27:104–105.
Wei SX. The clinical effectiveness of Danshen Injection combined with simvastatin in treating unstable angina pectoris. Youjiang Med (Chin) 2012;40:501–503.
Wu XH, Liang Q, Yang H, Wang YS, Zheng YH. Clinical study in 38 cases of Danshen Injection combined with simvastatin in treatment of acute cerebral Infarction. Jiangxi J Tradit Chin Med (Chin) 2010;41(7):23–24.
Yan LS, Liu XQ, Zhang Y. The clinical effectiveness of Danshen Injection in treatment of unstable angina pectoris. Chin Community Doctors (Chin) 2015;31(5):95–96.
Zhao QE. Clinical study in 66 cases of Danshen Injection in treatment of unstable angina pectoris. Chin Community Doctors (Chin) 2013;15(3):134.
Zhu Y, He YH. The clinical effect of Danshen Injection in treating patients with unstable angina pectoris. J Emerg Trad Chin Med (Chin) 2002;11:253–254.
Zhang SR, Xu LX, Gao QQ. Meta-analysis of the relationship between C-reactive protein level in Chinese population and prognosis of unstable angina pectoris. J Zhejiang Clin Med (Chin) 2006;8:344–345.
Wang ZY, Wang YQ, Li M. Analysis of 302 cases of adverse reactions occurred in Danshen Injection. Chin Pharm (Chin) 2010;21:3035–3037.
Wu JR, ed. Adverse reactions and safety of traditional Chinese medicine injections. Beijing: Chinese Press of Traditional Chinese Medicine; 2012:171.
0
浏览量
0
Downloads
2
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
